Skip to main content
Fig. 7 | BMC Medicine

Fig. 7

From: DNA methylation subtypes guiding prognostic assessment and linking to responses the DNA methyltransferase inhibitor SGI-110 in urothelial carcinoma

Fig. 7

Integrative analysis identifies SGI-110 target genes in T24 and UMUC-3 cells. A Summary of GSEA immune-related gene sets upregulated by SGI-110 in T24 and UMUC-3 cells. The “immune” sector is broken down further into specific pathways characterized as part of the interferon response, cytokines/chemokines, antigen presentation, inflammatory, and cancer testis antigen (CTA) categories. B, C Volcano plot of gene expression data obtained by RNA-seq in SGI-110-treated T24 and UMUC-3 cells compared to untreated cells. SGI-110 upregulated cytokine/chemokine genes are highlighted. D, E Changes in the expression of dsRNA defense genes after treatment with SGI-110. F, G The proportions of the read counts from endogenous retroviral long terminal repeats (LTRs), long interspersed nuclear elements (LINEs), and short interspersed nuclear elements (SINEs). H Heatmap of cancer testis antigen (CTA) expression in SGI-110-treated T24 and UMUC-3 cells compared to untreated cells. Gene expression was calculated as transcripts per million (TPM) values

Back to article page